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Background: The development of biomarkers predictive of response to immune
checkpoint inhibitor (ICI) therapies in advanced melanoma is an area of great interest
in oncology. Our study evaluated the potential role of serum vascular endothelial growth
factor (VEGF) as a predictive biomarker of clinical benefit and response to treatment
with ICIs.
Methods: Pre-treatment peripheral blood samples were obtained from advanced
melanoma patients undergoing ICI therapy as monotherapy or in combination at two
tertiary care hospitals in Western Australia. Serum VEGF levels were correlated with
response to therapy and survival outcomes.
Results: Serum VEGF samples were collected from a total of 130 patients treated with
ICI therapy (pembrolizumab 73, ipilimumab 15, and ipilimumab/nivolumab combination
42). Median serum VEGF level was significantly higher in the non-responders (82.15
pg/mL) vs. responders (60.40 pg/mL) in the ipilimumab monotherapy cohort (P <
0.0352). However, no difference was seen in VEGF levels between non-responders and
responders in pembrolizumab and ipilimumab/nivolumab treated patients.
Conclusions: The results of our study confirm previous observations that that high
pre-treatment serum VEGF levels in advanced melanoma patients may predict poor
response to ipilimumab. However, serum VEGF is not predictive of outcome in patients
treated with anti-PD-1 agents alone or in combination with ipilimumab.
Keywords: immunotherapy, vascular endothelial growth factor, melanoma, biomarker, ipilimumab,
pembrolizumab, nivolumab
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INTRODUCTION
Immune checkpoint inhibitors (ICIs) have improved the survival
of advanced melanoma patients with a 5 year survival rate of
about 50% (1, 2). However, a substantial proportion of patients
still do not benefit from this treatment. Biomarkers predictive of
response to ICI therapy in advanced melanoma are lacking. This
has important implications as ICI therapy is costly and can be
associated with immune adverse events leading to serious patient
morbidity (3).
A number of tumour and host related biomarkers predictive
of response to immunotherapy are currently being evaluated
(4). Although tissue-based biomarkers have been traditionally
considered the gold standard for predicting response to
treatment (5), a number of blood-based biomarkers are being
increasingly utilized in immuno-oncology (6). Serum lactate
dehydrogenase (LDH), neutrophil lymphocyte ratio, serum
albumin, and C reactive protein (CRP) have been evaluated for
their prognostic significance (7, 8). Blood based markers are
relatively non-invasive with an advantage of longitudinal sample
collection allowing us to potentially track an evolving anti-
tumour immune response. One such marker is serum vascular
endothelial growth factor (VEGF) (9).
Vascular endothelial growth factor (VEGF) mediates
immunosuppression through inhibition of dendritic cell
maturation, reduction of cytotoxic T-cell infiltration into
tumour and by creating an immunosuppressive tumour
microenvironment through upregulation of myeloid derived
suppressor cells (MDSCs) and regulatory T-cells (Tregs) (10, 11).
Combination of ICIs and anti-VEGF therapies has shown
synergy and positive outcomes in early clinical trials and this
approach is being evaluated in a number of trials across a range
of tumour types (10).
Yuan et al. (9) have previously demonstrated that pre-
treatment serum VEGF levels were associated with poor clinical
response and overall survival in advanced melanoma patients
treated with ipilimumab. The aim of our study was to evaluate
and further validate the prognostic biomarker significance of
serum VEGF levels in advanced melanoma patients treated with
anti-CTLA4 (ipilimumab), anti-PD1 agents (pembrolizumab/ or
nivolumab) or the combination of ipilimumab and nivolumab.
PATIENTS AND METHODS
Patient Selection
Advanced melanoma patients undergoing ICI therapy as
monotherapy (ipilimumab, pembrolizumab or nivolumab)
or combination therapy (ipilimumab and nivolumab) were
recruited from two hospitals in Perth, Western Australia.
Participants signed informed consent in accordance with
protocols safeguarding patient rights. All procedures were
accepted by the Human Research Ethics Committees at Edith
Cowan University (ECU) (No.11543) and Sir Charles Gairdner
Hospital (No. 2013-246).
Tumour responses were assessed radiologically by CT and/or
PET scans at two to three monthly intervals. Scans were reported
by radiologists blinded to patient treatment data. Patients were
defined as responders if they had significant reduction in tumour
size by RECIST 1.1 on CT or PET FDG avidity as per the
treating clinician or stable disease lasting more than 6 months.
Progression free survival (PFS) was defined as the time interval
between the start of therapy and the date of first progression.
Overall survival (OS) was defined as the time interval between
the start of therapy and death.
Measurement of Serum VEGF
Peripheral blood samples were obtained from each patient prior
to commencement (baseline) of treatment. Serum samples were
collected in SST tubes to assess serum concentrations of VEGF.
Samples were used undiluted and in duplicate, using aMilliplex R©
MAP Human Cytokine/Chemokine Magnetic Bead Panel kit
(EMD Millipore, USA) for 96 well plate assay using the protocol
provided by the manufacturer. xPONENT R© software (Luminex
Corp., USA) was used to detect, quantitate, and analyse the
samples on the Luminex 100TM instrument.
Statistical Analysis
Non-parametric Mann-Whitney U-tests were used to compare
VEGF levels. Patients were dichotomized based on high and low
serum VEGF concentrations. A cut-off value was calculated for
the ipilimumab treated cohort using CutoffFinder (12). Survival
curves were plotted using the Kaplan-Meier method and hazard
ratios computed through a Mantel-Cox analysis. Analyses were
performed using GraphPad Prism 7 (GraphPad Software, San
Diego, CA, USA) and IBM SPSS Statistics version 25 (IBM,
Armonk, NY, USA).










IIIC/D (unresectable) 9 7
IV (M1a) 17 13
IV (M1b) 15 12
IV (M1c) 57 44
IV (M1d) 31 24
BRAF STATUS
Wild type 82 64
Mutant 46 36
Unknown 1 1
*data not evaluable for one patient.
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FIGURE 1 | Comparison of serum VEGF levels between responders and non-responders to (A) ipilimumab, (B) pembrolizumab, and (C) ipilimumab/nivolumab
treatment.
FIGURE 2 | Kaplan–Meier curves of patients treated with ipilimumab (A,D) pembrolizumab (B,E) and ipilimumab/nivolumab (C,F), with high and low serum VEGF
levels on progression free survival (PFS) (A–C) and overall survival (OS) (D–F). (G) Cut-off finder curves representing the hazard rations (HR) and 95% Confidence
Intervals (CI) obtained a t multiple cut-off values from 70 to 160 pg/mL of serum VEGF.
Frontiers in Oncology | www.frontiersin.org 3 June 2020 | Volume 10 | Article 1041
Khattak et al. VEGF Level and Response to Immunotherapy
RESULTS
Serum samples were collected from a total of 130 patients treated
with ICI therapy as follows: pembrolizumab 73, ipilimumab
15, and ipilimumab/nivolumab combination 42. Baseline patient
characteristics are summarized in Table 1.
Serum levels VEGF was similar between the patient groups,
with 32–450 pg/mL in the ipilimumab group, 25–330 pg/mL
in anti-PDL1 treated group, and 24–490 pg/mL in the
combination group.
High serum VEGF level was associated with poor response to
treatment in the ipilimumab cohort. Median serum VEGF level
was significantly higher in the non-responders (82.15 pg/mL)
vs. responders (60.40 pg/mL) in the ipilimumab monotherapy
cohort (Figure 1A). No such difference was seen between
non-responders and responders in the pembrolizumab and
ipilimumab/nivolumab combination groups (Figures 1B,C).
Progression free survival (PFS) was worse in the ipilimumab
treated patients with a serum VEGF level >90 pg/mL vs. those
with a lower serum VEGF level (<90 pg/mL) (Figure 2A).
No significant differences in PFS were observed in the
pembrolizumab and ipilimumab/nivolumab cohorts based on
serum VEGF levels (Figures 2B,C). No differences in overall
survival were observed in any of the groups (Figures 2D–F). Cut-
off finder curves representing multiple cut-off values for serum
VEGF levels are demonstrated in Figure 2G.
DISCUSSION
Blood based biomarkers are becoming increasingly popular in
immuno-oncology, being relatively non-invasive and allowing
longitudinal sample collection enabling us to potentially track
an evolving immune response (6). A number of routine
blood based biomarkers including serum lactate dehydrogenase
(LDH), neutrophil lymphocyte ratio, serum albumin and C
reactive protein (CRP) have been evaluated for their prognostic
significance in previous studies (7, 8, 13, 14).
Serum VEGF level has been previously shown to be a negative
prognostic biomarker in ipilimumab treated patients (9). Here
we evaluated the prognostic biomarker significance of pre-
treatment serum VEGF levels in three different ICI treated
cohorts including those treated with anti-CTLA4 monotherapy,
the newer anti-PD1 agents as well as combination anti-PD1/anti-
CTLA4 therapy. Our results indicate reduced likelihood of
benefit from ipilimumab in the context of high serum VEGF
levels as demonstrated by Yuan et al. (9) in their study.
Serum VEGF levels have also been previously evaluated as
a predictive biomarker of response to identify patients more
suitable for treatment with interleukin 2 (IL-2) in advanced
melanoma (15). In this study serum VEGF and fibronectin were
identified as independent predictors of response. In particular,
high levels of serum VEGF correlated with reduced likelihood of
clinical response and poor overall survival with IL-2.
To our knowledge, the role of serum VEGF as a predictive
biomarker of response to anti-PD1 alone or in combination with
ipilimumab has not been previously evaluated. We did not see
any strong association between serum VEGF levels and response
in advanced melanoma patients treated with pembrolizumab or
combination ipilimumab and nivolumab. In these two cohorts,
there was no difference in median serum VEGF levels amongst
responders and non-responders and the PFS as well as OS were
similar in the two sub-groups based on serum VEGF levels.
In the Checkmate-067 phase 3 study, the greatest benefit of
combination ICI therapy was seen in the PD-L1 negative, BRAF
mutant and elevated LDH subgroups (16). Serum VEGF levels
should be further evaluated in a larger prospective study and
potentially help us identify a proportion of advanced melanoma
patients who might benefit from combination ICI therapy rather
than monotherapy. This will be a very useful finding as dual
therapy is associated with significant immune related adverse
events, often leading to hospitalization (16).
Vascular endothelial growth factor modulates anti-tumour
immune responses through poor antigen presentation due to
inhibition of dendritic cell maturation, interfering with T-
cell trafficking and creating an immune suppressed tumour
microenvironment through MDSCs and T-reg stimulation (10,
11, 17). Combination anti-PD1 and anti-VEGF therapies are
being currently evaluated in a number of clinical trials across a
range of tumour types due to the anticipated synergy from the
combination approach. Recently, there have been a few positive
studies reported in non-small lung cancer (18) and endometrial
cancer (19) evaluating this combination approach. Therefore, a
biomarker evaluating the VEGF pathway might be particularly
useful in future especially due to its potential to identify the subset
of patients who might be better suited to dual therapy rather
single agent ICI therapy.
There are a number of limitations of our study. The sample
size is small for the ipilimumab treated group, however, our
results confirm previous observations (9). There are some
differences in the baseline demographics between the cohorts
as this was not a randomized study. With the more common
use of first-line combination ipilimumab and nivolumab or
other clinical trials in the second-line setting, the number
of patients being treated with ipilimumab monotherapy has
significantly reduced in the last few years. There is no validated
cut off value for defining high vs. low serum VEGF levels,
and we based our survival analysis on the best cut-off for
the ipilimumab group. Nevertheless, using CutoffFinder we
did not find a VEGF concentration cut-off to distinguish
survival in patients treated with anti-PD-1 agents. We did not
evaluate post treatment serum VEGF levels for comparison
with treatment outcomes. However, Yuan et al. (9) did not
find a significant change in serum VEGF after induction
completion (week 12).
In conclusion, our results suggest that serum VEGF level
in advanced melanoma patients may indicate poor response to
ipilimumab, however it does not impact response to anti-PD-1
agents alone or in combination with ipilimumab. Future research
could focus on evaluating the biomarker significance of serum
VEGF levels in prospective clinical trials of ICI therapy.
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